Division of Neurobiology, Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York, USA.
Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H397-407. doi: 10.1152/ajpheart.00679.2010. Epub 2010 Oct 22.
Hypertension alters cerebrovascular regulation and increases the brain's susceptibility to stroke and dementia. We investigated the temporal relationships between the arterial pressure (AP) elevation induced by "slow pressor" angiotensin II (ANG II) infusion, which recapitulates key features of human hypertension, and the resulting cerebrovascular dysfunction. Minipumps delivering saline or ANG II for 14 days were implanted subcutaneously in C57BL/6 mice (n = 5/group). Cerebral blood flow was assessed by laser-Doppler flowmetry in anesthetized mice equipped with a cranial window. With ANG II (600 ng · kg(-1) · min(-1)), AP started to rise after 9 days (P < 0.05 vs. saline), remained elevated at 11-17 days, and returned to baseline at 21 days (P > 0.05). ANG II attenuated the cerebral blood flow increase induced by neural activity (whisker stimulation) or endothelium-dependent vasodilators, an effect observed before the AP elevation (7 days), as well as after the hypertension subsided (21 days). Nonpressor doses of ANG II (200 ng · kg(-1) · min(-1)) induced cerebrovascular dysfunction and oxidative stress without elevating AP (P > 0.05 vs. saline), whereas phenylephrine elevated AP without inducing cerebrovascular effects. ANG II (600 ng · kg(-1) · min(-1)) augmented neocortical reactive oxygen species (ROS) with a time course similar to that of the cerebrovascular dysfunction. Neocortical application of the ROS scavenger manganic(I-II)meso-tetrakis(4-benzoic acid)porphyrin or the NADPH oxidase peptide inhibitor gp91ds-tat attenuated ROS and cerebrovascular dysfunction. We conclude that the alterations in neurovascular regulation induced by slow pressor ANG II develop before hypertension and persist beyond AP normalization but are not permanent. The findings unveil a striking susceptibility of cerebrovascular function to the deleterious effects of ANG II and raise the possibility that cerebrovascular dysregulation precedes the elevation in AP also in patients with ANG II-dependent hypertension.
高血压改变脑血管调节功能,增加大脑患中风和痴呆的易感性。我们研究了“缓慢升压”血管紧张素 II(ANG II)输注引起的动脉压(AP)升高与由此导致的脑血管功能障碍之间的时间关系,这种输注方式重现了人类高血压的关键特征。装有盐水或 ANG II 的迷你泵通过皮下植入 C57BL/6 小鼠(每组 5 只)。在配备颅窗的麻醉小鼠中通过激光多普勒血流仪评估脑血流。用 ANG II(600ng·kg(-1)·min(-1))输注,AP 在第 9 天开始升高(P < 0.05 与盐水相比),在 11-17 天期间保持升高,在 21 天恢复到基线(P > 0.05)。ANG II 减弱了神经活动(胡须刺激)或内皮依赖性血管扩张剂引起的脑血流增加,这种作用在 AP 升高之前(第 7 天)以及高血压消退后(第 21 天)观察到。非升压剂量的 ANG II(200ng·kg(-1)·min(-1))引起脑血管功能障碍和氧化应激,而不升高 AP(P > 0.05 与盐水相比),而苯肾上腺素升高 AP 而不引起脑血管作用。ANG II(600ng·kg(-1)·min(-1))以与脑血管功能障碍相似的时间进程增加新皮层活性氧物种(ROS)。新皮层应用 ROS 清除剂锰(I-II)-meso-四(4-苯甲酸)卟啉或 NADPH 氧化酶肽抑制剂 gp91ds-tat 减弱了 ROS 和脑血管功能障碍。我们得出结论,由缓慢升压 ANG II 引起的神经血管调节改变发生在高血压之前,并持续到 AP 正常化之后,但不是永久性的。这些发现揭示了脑血管功能对 ANG II 有害影响的惊人易感性,并提出了在依赖 ANG II 的高血压患者中,脑血管调节失调可能先于 AP 升高的可能性。